VRX.TO - Valeant Pharmaceuticals International, Inc.

Toronto - Toronto Delayed Price. Currency in CAD
25.39
+0.28 (+1.12%)
At close: 4:00PM EST
Stock chart is not supported by your current browser
Previous Close25.11
Open25.17
Bid25.30 x 0
Ask25.40 x 0
Day's Range24.58 - 26.13
52 Week Range11.20 - 29.28
Volume5,137,969
Avg. Volume1,941,961
Market Cap8.72B
BetaN/A
PE Ratio (TTM)6.48
EPS (TTM)3.92
Earnings DateFeb 26, 2018 - Mar 2, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est18.71
  • CNW Group14 hours ago

    Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Tender Offers For Senior Notes

    LAVAL, Quebec, Dec. 15, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE:VRX - News) (TSX:VRX.TO - News) ("Valeant") announced today the results to date of the pending cash tender offers (the "Tender Offers") by Valeant and Valeant Pharmaceuticals International ("VPI," and together with Valeant, the "Offerors"), a wholly-owned subsidiary of Valeant, to purchase up to $1,500,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of their respective outstanding notes listed in the table below (collectively, the "Notes"), as well as the anticipated early settlement date for the Tender Offers on December 18, 2017 (the "Early Settlement Date"). Valeant is the Offeror for the notes issued by it, and VPI is the Offeror for the notes issued by it.

  • PR Newswire14 hours ago

    Valeant And One Of Its Subsidiaries Announce Early Tender Results And Early Settlement Date For Cash Tender Offers For Senior Notes

    LAVAL, Quebec, Dec. 15, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (VRX) (VRX) ("Valeant") announced today the results to date of the pending cash tender offers (the "Tender Offers") by Valeant and Valeant Pharmaceuticals International ("VPI," and together with Valeant, the "Offerors"), a wholly-owned subsidiary of Valeant, to purchase up to $1,500,000,000 aggregate principal amount (the "Aggregate Maximum Purchase Amount") of their respective outstanding notes listed in the table below (collectively, the "Notes"), as well as the anticipated early settlement date for the Tender Offers on December 18, 2017 (the "Early Settlement Date"). Valeant is the Offeror for the notes issued by it, and VPI is the Offeror for the notes issued by it.

  • 2 Fallen Stars That Will Fly High Again
    The Motley Fool20 hours ago

    2 Fallen Stars That Will Fly High Again

    BlackBerry Ltd. (TSX:BB)(NYSE:BB) and Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) are two businesses that have reinvented themselves. Here's why you should jump back in to these once-market-darlings.

  • 4 Non-Cannabis Stocks That Have Grown 25% in the Past 3 Months
    The Motley Fool21 hours ago

    4 Non-Cannabis Stocks That Have Grown 25% in the Past 3 Months

    Bombardier, Inc. (TSX:BBD.B) and these three other stocks could provide investors with excellent growth opportunities.

  • Barrons.com22 hours ago

    Valeant: A Real Bounceback or a Dead Cat?

    Shares of Valeant Pharmaceuticals International (VRX) are higher on Friday, recovering from a downgrade from JPMorgan yesterday, but investors shouldn't get too comfortable, warns Mizuho Securities.  Analyst Irina Koffler reiterated an Underperform rating on the stock today, although she did raise he price target from $7 to $10. Koffler writes that while 2018 EBITDA guidance may not be "that disappointing," but she's not willing to abandon her bear thesis ahead of it.

  • Why Sanderson Farms, Valeant Pharmaceuticals International, and Criteo Slumped Today
    Motley Fool2 days ago

    Why Sanderson Farms, Valeant Pharmaceuticals International, and Criteo Slumped Today

    Find out the latest company that mentioned the NFL's impact on its business.

  • Barrons.com2 days ago

    Valeant: Down It Goes!

    Everything's been going so well for Valeant Pharmaceuticals International (VRX). See, Valeant has been on quite a run. Since bottoming at $8.51 in April, Valeant's shares have rallied more than 130% as the beleaguered pharmaceutical company sold off assets, and paid down or extended its debt.

  • MarketWatch2 days ago

    These 4 stocks are powering higher

    News and strong technical momentum are behind these gains.

  • Market Realist2 days ago

    Valeant Pharmaceuticals’ Siliq Approved for Plaque Psoriasis

    In February 2017, the FDA (Food and Drug Administration) approved Valeant Pharmaceuticals' (VRX) Siliq injection for the treatment of adults with moderate to severe plaque psoriasis.

  • MarketWatch2 days ago

    Valeant's stock drops after J.P. Morgan turns bearish

    Shares of Valeant Pharmaceuticals International Inc. dropped 4.3% in premarket trade Thursday, after the drug maker was downgraded at J.P. Morgan, which cited valuation and concerns over patent losses ...

  • Valeant (VRX) Touches 52-Week High: Is the Stock Officially Back?
    Zacks3 days ago

    Valeant (VRX) Touches 52-Week High: Is the Stock Officially Back?

    Shares of Valeant Pharmaceuticals (VRX) surged more than 2% higher on Wednesday morning, touching a new 52-week high in the process. As we approach the New Year, it is time to ask: is Valeant officially back?

  • Queue the 2018 Rebound for Valeant Pharmaceuticals Intl Inc.
    The Motley Fool3 days ago

    Queue the 2018 Rebound for Valeant Pharmaceuticals Intl Inc.

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) may be slated to enjoy a huge 2018. Here's why investors may want to back up the truck while shares are still cheap.

  • Valeant Pharmaceuticals International Inc. Is Trading at 52-Week Highs: Should You Buy or Sell?
    The Motley Fool4 days ago

    Valeant Pharmaceuticals International Inc. Is Trading at 52-Week Highs: Should You Buy or Sell?

    Valeant Pharmaceutical International Inc. (TSX:VRX)(NYSE:VRX) is still in early stages of a comeback, with many hurdles to overcome.

  • Barrons.com4 days ago

    This Porridge Is Too Hot: Valeant Bears Abandon the Stock

    Shares of Valeant Pharmaceuticals International (VRX) are higher Tuesday, and have easily outperformed this year, to the point that shorts may be throwing in the towel. Today, Cantor Fitzgerald's Louise Chen and her team write that the company has also seen the largest decrease in short interest in her coverage universe as of the end of November. The move comes as Valeant rose from less than $15 in mid-month to nearly $22 today.

  • Valeant Pharmaceuticals Intl Inc.’s Recent Debt Offering a Genius Move
    The Motley Fool4 days ago

    Valeant Pharmaceuticals Intl Inc.’s Recent Debt Offering a Genius Move

    By refinancing $1.5 billion of debt due in 2020, Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) CEO Joe Papa has continued to impress the market in his attempt to turn Valeant around. Here's more.

  • Valeant (VRX) in Focus: Stock Moves 11.7% Higher
    Zacks5 days ago

    Valeant (VRX) in Focus: Stock Moves 11.7% Higher

    Valeant Pharmaceuticals International (VRX) was a big mover last session, as the company saw its shares rise nearly 12% on the day.

  • Valeant Pharmaceuticals Intl Inc. Surges ~12% in a Day: Why the Stock Could Easily Double in 2018
    The Motley Fool5 days ago

    Valeant Pharmaceuticals Intl Inc. Surges ~12% in a Day: Why the Stock Could Easily Double in 2018

    Valeant Pharmaceuticals Intl Inc. (TSX:VRX)(NYSE:VRX) surged along with the biotech and pharma industry. Here's why investors should expect more big days in 2018.

  • TSX posts two-week high as industrials lead broad-based rally
    Reuters8 days ago

    TSX posts two-week high as industrials lead broad-based rally

    Canada's main stock index rose to a two-week high on Friday, led by financial and industrial shares after solid U.S. jobs data boosted investor sentiment, while energy stocks climbed on higher oil prices. ...

  • What's Behind Valeant Pharmaceuticals Inc.'s 11% Move Higher?
    Motley Fool8 days ago

    What's Behind Valeant Pharmaceuticals Inc.'s 11% Move Higher?

    Carryover news and a broad market rally appear to be fueling Valeant's stock on an event-free day.

  • Baystreet8 days ago

    Aecon at 52-Week High on News

    Aecon Group Inc. (T.ARE) hit a new 52-week high of $20.01 Friday. Aecon Group announced the receipt ...

  • PR Newswire9 days ago

    Valeant To Participate At The BMO Capital Markets 2017 Prescriptions for Success Healthcare Conference

    LAVAL, Quebec , Dec. 7, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (NYSE: VRX and TSX: VRX) ("Valeant") today announced that Scott A. Hirsch , senior vice president and ...

  • The Undeniable Reason Behind Valeant Pharmaceuticals Inc.'s 43% Rally in November
    Motley Fool10 days ago

    The Undeniable Reason Behind Valeant Pharmaceuticals Inc.'s 43% Rally in November

    Baby steps have been taken, but there's still a long way for this company to go.

  • Valeant Pharmaceuticals Joins Elite Club Of Stocks With RS Ratings Over 90
    Investor's Business Daily11 days ago

    Valeant Pharmaceuticals Joins Elite Club Of Stocks With RS Ratings Over 90

    Valeant Pharmaceuticals sees its Relative Strength Rating move into the elite 90-plus level.

  • PR Newswire12 days ago

    Valeant Announces Pricing Of Private Offering Of Senior Notes

    LAVAL, Quebec, Dec. 4, 2017 /PRNewswire/ -- Valeant Pharmaceuticals International, Inc. (VRX) (VRX) ("Valeant" or the "Company") announced today that it has priced its previously announced offering of 9.000% senior notes due 2025 (the "Notes"). Valeant intends to use the net proceeds from this offering, along with cash on hand, to repurchase $1,500,000,000 aggregate principal amount of outstanding notes pursuant to a tender offer announced earlier today, including Valeant Pharmaceuticals International's, a wholly-owned subsidiary of the Company, outstanding 7.000% Senior Notes due 2020 and 6.375% Senior Notes due 2020 and up to $200,000,000 of the Company's outstanding 5.375% Senior Notes due 2020, and to pay related fees and expenses. The Notes will be guaranteed by each of the Company's subsidiaries that are guarantors under the Company's credit agreement and the Company's existing senior notes.

  • CNW Group12 days ago

    Valeant Announces Pricing Of Private Offering Of Senior Notes

    LAVAL, Quebec, Dec. 4, 2017 /CNW/ -- Valeant Pharmaceuticals International, Inc. (NYSE:VRX - News) (TSX:VRX.TO - News) ("Valeant" or the "Company") announced today that it has priced its previously announced offering of 9.000% senior notes due 2025 (the "Notes"). Valeant intends to use the net proceeds from this offering, along with cash on hand, to repurchase $1,500,000,000 aggregate principal amount of outstanding notes pursuant to a tender offer announced earlier today, including Valeant Pharmaceuticals International's, a wholly-owned subsidiary of the Company, outstanding 7.000% Senior Notes due 2020 and 6.375% Senior Notes due 2020 and up to $200,000,000 of the Company's outstanding 5.375% Senior Notes due 2020, and to pay related fees and expenses. The Notes will be guaranteed by each of the Company's subsidiaries that are guarantors under the Company's credit agreement and the Company's existing senior notes.